solute carrier family 22 member 9Genealiases: HOAT4 · OAT4 · OAT7 · UST3H · ust3
Q-omics provides the consensus-scored SLC22A9 profile across patient tissues and cancer cell-line models. SLC22A9 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SLC22A9 is differentially expressed in 6, with the highest sampling consensus in CHOL. Additionally, SLC22A9 RNA expression shows 16,864 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, CHOL, and GBM as cancer lineages where SLC22A9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC22A9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC22A9 survival associations across molecular data types. SLC22A9 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC22A9 RNA expression–survival associations across cancer types. High SLC22A9 expression shows unfavorable associations in UCEC, CHOL, KICH and ACC, but favorable associations in UVM and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for SLC22A9 RNA expression.
This table summarizes SLC22A9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC22A9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC22A9 shows lower tumor expression in CHOL, KIRP, KICH and THCA and higher tumor expression in HNSC and LUSC. The CHOL box plot shows higher SLC22A9 RNA expression in normal versus tumor tissue (log2 FC = −3.337, t-test p < 0.001).
This table shows molecular features associated with SLC22A9 in patient tissues and cancer cell lines. In patient samples, SLC22A9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC22A9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
